-+ 0.00%
-+ 0.00%
-+ 0.00%

Hoth Therapeutics Engages With ICON Clinical Research To Expand Phase II Clinical Trial For Cancer Patients Suffering From Skin Toxicities Associated With EGFRi

Benzinga·07/29/2025 11:59:56
Listen to the news

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries

NEW YORK, July 29, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharma innovator, today announced its engagement with ICON Clinical Research Limited ("ICON") to expand it's Phase II Clinical Trial for cancer patients suffering from skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).

Additional regulatory approval for the Phase II clinical trial is expected from potentially three EU countries in the upcoming months.  The EU approval is part of the Company's international clinical development strategy for HT-001. The trial is currently enrolling patients in multiple sites in the United States. This Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi. More information can be found at www.hoththerapeutics.com.